Local injection of OK432 can augment the TH1-type T-cell response in tumor-draining lymph node cells and increase their immunotherapeutical potential

International Journal of Cancer

Volumn 70, Issue 5, 1997, Pages 598-605

  Okamoto, Tadao ^a,b   Harada, Mamoru ^a   Tamada, Koji ^a   Yoshida, Hiroki ^a   Ito, Osamu ^a   Kong, Young Yun ^a   Takenoyama, Mitsuhiro ^a   Hirashima, Chikashi ^a   Matsuzaki, Goro ^a   Nomoto, Kikuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Green Cross Company   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PICIBANIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HELPER CELL; LYMPH NODE CELL; LYMPHOCYTE PROLIFERATION; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; IMMUNITY, CELLULAR; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKIN-4; LYMPH NODES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; PICIBANIL; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

EID: 0030896015     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970304)70:5<598::AID-IJC18>3.0.CO;2-9     Document Type: Article

References (30)

1. CHOMCZYNSKI, P. and SACCHI, N., Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chlorotbrm extraction. Anal. Biochem., 162, 156-159 (1987).
2. GOLUMBEK, P., LAZENBY, A., LEVITSKY, H., JAFFEE, J-. KARASUYAMA, H., BAKER, M. and PARDOLL. D., Treatment of established renal cancer by tumor cells engineered to secrete IL-4. Science. 254, 713-716 (1991).
3. GREENBERG, P.D., Adoptive T cell therapy of tumor: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol., 49, 281-355 (1991).
4. + T-cells show antitumor activity against syngeneic fibrosarcoma. Cancer Res., 53, 106-111 (1993).
5. HARADA, M., OKAMOTO, T., OMOTO, K., TAMADA, K., TAKENOYAMA, M., HIRASHIMA, C., ITO, O., KIMURA, G. and NOMOTO, K., Specific immunotherapy with tumour-draining lymph node cells cultured with both anti-CD3 and ami-CD28 monoclonal antibodies. Immunology, 87, 447-453 (1996).
6. KAI, S., TANAKA, J., KIKUO, K. and TORISU, M., Studies on the immunopotentiating effects of a streptococcal preparation, OK-432. Clin. exp. Imnwnol., 37, 98-105 (1979).
7. KAWAGUCHI, T., SUEMATSU, M., KOIZUMI, H., MITSUI, H., SUZUKI, S., MATSUNO, T., OGAWA, H. and NOMOTO, K., Activation of macrophage function by intraperitoneal administration of the streptococcal agent OK-432. Immunopharmacology. 6, 177-189 (1983).
8. KITAMVRA, K., MATSUDA, K., IDE, M., TOKUNAGA, T. and HONDA, M., A fluorescence sandwich ELISA for detection soluble and cell-associated human interleukin-2. J. Immunol. Meth., 121, 281-288 (1989).
9. KOBAYASHI, M., FITZ, L., RYAN, M., HEWICK, R.M., CLARK, S.C., CHAN, S., LONDON, R., SHERMAN, F., PERUSSIA, B. and TRINCHIERI, G., Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. exp. Med., 170, 827-845 (1989).
10. KUROSAWA, S., MATSUZAKI, G., HARADA, M., ANDO, T. and NOMOTO, K., Early appearance and activation of natural killer cells in turn or-in filtrating lymphoid cells during tumor development. Europ. J. Immunol., 23, 1029-1033 (1993).
11. MORIYA, Y., SATO, H., ITOH, K., SAITO, M., YOSHIDA, T. and ISHIDA, N., Induction of antitumor L3T4-positive T cells by OK-432 at tumor sites in mice. Cancer Immunol. Imnumother., 36, 245-250 (1993).
12. + T cells. Immunol. Rev., 123, 209-229 (1991).
13. + T cells as Th1 cells based on lymphokine secretion and functional properties. J. Immunol., 144, 4898-4905 (1990).
14. OKAMOTO, T., HARADA, M., SHINOMIYA, Y., MATSUZAKI, G. and NOMOTO, K., The anti-tumor effect of tumor-draining lymph node cells activated by both anti-CD3 mAb and activated B cells as costimulatory signal-providing cells. Cancer Imnumol. Immunother., 40, 173-181 (1995).
15. - T-cells. Cancer Res., 50, 4630-4634 (1990).
16. POLLACK, S P., OK-432 stimulates primary production and activity of murine natural killer cells. Cell Grvwth Regul., 6, 224-223 (1987).
17. SAITO, M., NANJO, M., KATAOKA, M., MORIYA, Y., SUGAWARA, Y., YOSHIDA, T. and ISHIDA, N., Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumor sites in mice. Cancer Res., 48, 4163-4167 (1988).
18. SUZUKI, F., KOBAYASHI, M. and POLLARD, R.B., Effect of interleukin 4 on lung metastases in murine B16 melanoma. J. Immunol., 150, 1244 (1993).
19. TAMADA, K., HARADA, M., OKAMOTO, T., TAKENOYAMA, M., ITO. O., MATSUZAKI, G. and NOMOTO, K., Specific antitumor activity of tumorinriltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2. Cancer Immunol. Immunther., 41, 339-347 (1995).
20. TANIGUCHI, T., MATSUI, H., FUJITA, T., TAKAOKA, C., KASHIMA, N., YOSHIMOTO, R. and HAMURA, J., Structure and expression of a cloned cDNA for human interleukin-2. Nature (Lond.), 302, 305-310 (1983).
21. + T cells may be a potent effector against poorly immunogenic syngeneic tumors. Biotherapy, 8, 143-151 (1995).
22. TORISU, M., KATANO, M., KIMURA, Y., ITOH, H. and TAKESUE, M., New approach to management of malignant ascites with a streptococcal prepara- tion, OK-432. Improvement of host immunity and prolongation of survival. Surgery, 93, 357-364 (1983).
23. TRINCHIERI, G. and SCOTT, P., The role of IL-12 in the immune response, disease and therapy. Immunol. Today, 15, 460-463 (1994).
24. UCHIDA, A. and HOSHINO, T., Clinical studies on cell-mediated immunity in patients with malignant disease: effects of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitoeen responsivenevs in vitro. Cancer, 45, 476-483 (1980).
25. UCHIDA, A.and KLEIN, E., Activation of human blood lymphocytes and monocytes by the streptococcal preparation OK432: enhanced generation of soluble cytotoxic factors. Immunol. Lett., 10, 177-181 (1985).
26. UCHIDA, A. and MICKSCHE, M., Lysis of fresh tumor cells by autologous peripheral blood and pleural effusion lymphocytes activated by OK-432. J. nut. Cancer lust., 71, 673-680 (1983).
27. WATABE, S., SSENDO, F. KIMURA, S. and ARAI, S., Activation of cytotoxie polymorphonuclear leukocytes by in vivo administration ot a streptococcal preparation (OK-432). J. nat. Cancer Inst., 72, 1365-1370 (1984).
28. WATANABE, Y. and IWA, T., Clinical value of immunotherapy for lung cancer by the streptococcal preparation, OK-432. Cancer. 52, 248-253 (1984).
29. YOSHIZAWA, H., CHANG, A.E. and SHU, S., Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol., 147, 729-737 (1991).
30. YOSHIZAWA, H., CHANG, A.E. and SHU. S., Cellular interactions in effecter cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated lumor-drainins lymph node cells. Cancer Res., 52, 1129-1134 (1992).